Home » Topics » Regulatory » EMA

EMA
RSS

EMA committee supports approval of Endoceutics' Intrarosa

Nov. 15, 2017

EMA grants accelerated assessment to patisiran for hereditary ATTR amyloidosis

Nov. 14, 2017

EMA grants orphan drug designation to Debio-1347

Nov. 14, 2017

EMA confirms further restrictions on use of Zinbryta

Nov. 14, 2017

EMA committee backs approval of Jorveza as treatment for eosinophilic esophagitis

Nov. 14, 2017

Shire's Adynovi receives positive opinion in E.U.

Nov. 14, 2017

EMA recommends Prevymis for marketing authorization

Nov. 14, 2017

EMA grants positive opinion for Ocrevus as treatment for patients with RMS or PPMS

Nov. 14, 2017

EMA grants PRIME designation to Mereo's BPS-804

Nov. 13, 2017

EMA committee confirms refusal of Fanaptum MAA

Nov. 13, 2017

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...